abbreviatioNs AA = anaplastic astrocytoma; ALA = 5-aminolevulinic acid; CTC = Common Toxicity Criteria; GBM = glioblastoma multiforme; HR = hazard ratio; IDH1 = isocitrate dehydrogenase; KPS = Karnofsky Performance Scale; mAB = monoclonal antibody; MGMT = O 6 -methylguanine-DNA methyltransferase; OS = overall survival; RC = resection cavity; RIT = radioimmunotherapy; RPA = recursive partitioning analysis; RTOG = Radiation Therapy Oncology Group. submitted September 16, 2014. accepted December 12, 2014. iNclude wheN citiNg Published online July 3, 2015; DOI: 10.3171/2014.12.JNS142168. disclosure The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. This work was supported by grants from the German research foundation DFG (GO998/1-1), the Deutsche Krebshilfe (10-1782-GO2), and a fund of the MMW Foundation (Verein zur Förder-ung von Wissenschaft und Forschung an der Medizinischen Fakultät der LMU München e.V.). * Drs. Reulen and Poepperl contributed equally to this work. results Median OS of patients with AA was 77.2 months (95% CI 30.8 to > 120). Five AA patients (33%) are currently alive, with a median observation time of 162.2 months. Median OS of all 40 patients with GBM was 18.9 months (95% CI 15.8-25.3), and median OS was 25.3 months (95% CI 18-30) for those patients treated with the 131 I-mAB. Three GBM patients are currently alive. One-, 2-, and 3-year survival probabilities were 100%, 93.3%, and 66.7%, respectively, for AA patients and 82.5%, 42.5%, and 15.9%, respectively, for GBM patients. Restratification of GBM patients by recursive partitioning analysis (RPA) Classes III, IV, and V produced median OSs of 31.1, 18.9, and 14.5 months, respectively (p = 0.004), which was higher than expected. Multivariate analysis confirmed the role of RPA class, age, and treatment in predicting survival. No Grade 3 or 4 hematological, nephrologic, or hepatic toxic effects were observed; 4 patients developed Grade 3 neurological deficits. Radiological signs of radionecrosis were observed in 6 patients, who were all responding well to steroids. coNclusioNs Median OS of GBM and AA patients treated with 131 I-mABs reached 25.3 and 77.2 months, respectively, thus markedly exceeding that of historical controls. Adverse events remained well controllable with the fractionated dosage regimen.
blood-brain barrier, ensures higher concentrations of the drug at its destination, and reduces the risks of systemic therapy.
Glioma cells are known to express specific receptors or glycoproteins that can be used as biological targets for treatment. A well-examined target is tenascin-C, an extracellular matrix glycoprotein ubiquitously expressed by malignant gliomas, but only minimally expressed in normal brain tissue. 13, 37 Studies with anti-tenascin monoclonal antibodies (mABs) labeled with iodine-131 or yttrium-90 and applied in the postoperative RC via an Ommaya reservoir have demonstrated very promising results regarding prolonged survival in patients with malignant gliomas. 3, 4, 12, [25] [26] [27] [29] [30] [31] It is assumed that the radioimmunoconjugate travels through the tissue, binds to tumor cells, and exerts its effect by radiation-mediated DNA damage. 9, 15, 31, 39 With the recent availability of new mABs, 7, 9, 17, 36 smaller compounds such as peptides, and tailored antibody fragments, 9, 14 there is resurging interest in this promising approach.
Intracavitary application of radiolabeled mABs has been performed either as a fixed single high dose 3, 4, [25] [26] [27] or as fractionated lower doses. 12, [29] [30] [31] However, follow-up for these studies was only between 1 and 3 years. In this report, we present the results of a 55-patient cohort prospectively treated with fractionated radioimmunotherapy (RIT) and followed over time to allow for long-term analysis (> 10 years) of survival, adverse events, and treatment toxicity. Initial results describing the feasibility of and experiences with this technique in a first group of patients have been reported previously. 12 One aspect of the present study was to evaluate the effects of different fractionation regimens on long-term outcomes.
methods patients and selection criteria
Fifty-five patients suffering from malignant glioma were treated with RIT in a prospective observational study between 1996 and 2003. The first patients were treated in cooperation with the Department of Nuclear Medicine in Cesena, Italy; all other patients were treated at the University Hospital in Munich. The study protocol was approved by the ethical review board of the Ludwig Maximilian University Munich. Patients had to understand and sign written informed consent before participating in the study. Eligible patients were between 18 and 70 years old, had a histologically confirmed supratentorial World Health Organization (WHO) Grade III (n = 15) or IV (n = 40) tumor with positive immunoreactivity for tenascin, and a Karnofsky Performance Scale (KPS) score of at least 70% at study entry. Total or near-total resection, according to early postoperative MRI (within 72 hours, residual tumor volume 0-3.0 cm 3 ), was an essential entry criterion. Standard fractionated radiotherapy (60 Gy) should have been completed prior to study entry. Exclusion criteria were multifocal glioma manifestations, massive tumor progression during radiotherapy, other malignancies (apart from basaliomas), pregnancy, or severe medical comorbidity with reduced life expectancy. If a test dose of technetium-99m human serum albumin ( 99m Tc HSA), injected into the cavity, showed leakage into CSF spaces or ventricles on scintigraphy, patients were excluded from treatment.
study design and Follow-up
Surgeons operated on patients using 5-aminolevulinic acid (ALA) fluorescence-guided resection. 33 If a ventricle was opened during surgery, the opening was sealed with a collagen or a gelatin sponge saturated with fibrin glue. Standard fractionated radiotherapy consisted of irradiation of the tumor bed and a 2-to 3-cm peritumoral margin at a dose of 2 Gy per fraction; patients were given 5 doses per week for a total radiation dose of 60 Gy. An Ommaya reservoir was implanted with its catheter reaching into the RC. Prior to each treatment cycle, MRI (MPRAGE sequence) was performed to document treatment effects or tumor progression and to determine the volume of the tumor cavity by segmentation. Also prior to each treatment cycle, the KPS and neurological status were recorded, and laboratory tests for blood count, liver, and kidney functions were performed. Concomitant medications were started 1 day before each RIT cycle and consisted of dexamethasone (12 mg for 3 days, tapered thereafter), antiepileptic medication (phenytoin), and a mild analgetic medication. Patients receiving 131 I-mAB (iodine-131−labeled anti-tenascin monoclonal antibody) were given potassium iodine (0.3 g/day until Day 10 after treatment) for protecting the thyroid from radiation. Since progression-free survival (PFS) was not a prespecified endpoint, the follow-up MRIs were not performed with the necessary technical accuracy to allow retrospectively a precise and meaningful volumetric progression analysis.
For injection of the 131 I-mAB or yttrium-90−labeled anti-tenascin monoclonal antibody ( 90 Y-mAB), respectively, the Ommaya reservoir was accessed with a 20-gauge port access needle using sterile technique. The mAB was dissolved in a volume of 1-3.5 ml saline (depending on the volume of the RC) and injected into the reservoir. Patients were isolated in a shielded room until whole body retention, as measured by the local radiation dose rate, reached the level required by national regulations. Patients treated with 131 I could usually be dismissed after 5-7 days. To document stability of the radioimmunoconjugate in some patients, small liquid probes were removed from the RC 5 days after treatment.
Three treatment regimens were tested in the course of this study. Initially, a comparison was planned using I-mAB (Group B, dose = 30 mCi/1110 MBq per cycle) for 5 treatment cycles each with a 6-week interval between the cycles. The doses used in our study were recommended by Riva et al. 30, 31 Groups of 2-3 eligible patients alternatively received either or "cumulative dose" in this context indicates the administered amount of radioactivity and not the absorbed dose of the treated tissue.
After the completion of RIT, MRI was repeated every 3 months in the 1st year and every 6 months thereafter. In all patients [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) was performed. In the event of significant contrast enhancement on MRI where radionecrosis was suspected, a O- (2-[18F] fluorethyl)-l-tyrosine PET (FET-PET) was performed to differentiate recurrence from radionecrosis. 24 A lack of amino acid uptake in the FET-PET supports the diagnosis of radionecrosis and vice versa. All adverse events and complications related to therapy were documented, including laboratory values, neurology, skin necrosis, or radionecrosis.
In the case of tumor progression, systemic chemotherapy or repeat surgery was allowed following RIT. Since both are regarded as a possible source of bias with effects on survival, additional therapies were analyzed according to their frequency.
antibodies and radiolabeling
The murine IgG 1 antibodies BC-4 and BC-24 used for this study were directed against tenascin. BC-4 and BC-24 recognize an epitope within the epidermal growth factor-like sequence that is present in all tenascin isoforms. I (1.1-1.85 GBq/patient) by a simplified and modified iodogen method, and radioimmunoconjugate stability and residence time in the RC were described previously. 23, 30, 38 adverse events and toxicity Adverse events were classified according to the grading system of the US National Cancer Institute Common Toxicity Criteria (CTC), version 2.0. Grades 0, 1, and 2 correspond to no, mild, or moderate symptoms (medical intervention not indicated); and Grades 3 and 4 correspond to severe and life-threatening symptoms, respectively (medical intervention indicated). The precise etiology of neurological deficits following RIT application was often difficult to reliably distinguish from the effects of recurrent tumor growth. The toxic effects of radiation (radionecrosis) were recorded using FDG-PET in combination with MRI (in selected cases, FET-PET was also used).
histology
Histology was reviewed by 2 independent neuropathologists (local neuropathologist and Brain Tumor Reference Center of the DGNN [German Society for Neuropathology and Neuroanatomy] located at the Department of Neuropathology, University of Bonn). Tenascin expression was investigated in either fresh or paraffin-embedded tissue according to standard immunohistochemical methods using a murine tenascin antibody (BC4). MGMT promoter methylation status (methylation-specific polymerase chain reaction [PCR] ) and IDH1 mutation status were analyzed retrospectively in a subset of patients from the retrospective analysis for whom sufficient tumor material was available at the time of follow-up (Table 1) . 16, 20 end points and statistical analysis
In this prospective observational study, efficacy and safety of RIT were assessed. According to a recent Cochrane report, observational studies report results comparable to similarly conducted randomized controlled trials. 2 The primary end point was overall survival (OS), and the secondary end points were adverse events and toxicity. Since the study was not randomized, it was assumed that there were imbalances or selection effects within or between the groups. Therefore, factors leading to bias and asymmetry that possibly affected survival were carefully analyzed, and statistical measures were taken to adjust for such bias.
The mean, standard deviation, median, range, and 95% confidence interval were calculated using conventional methods. Differences in sex, age, and between groups were computed using the Mann-Whitney U-test and Kruskal-Wallis test. All statistical tests were 2-sided, and the level of significance was set at p = 0.05. Pearson's chisquare tests or Fisher's exact tests were applied for testing primary efficacy parameters. The method of Kaplan and Meier was used to estimate survival distributions measured from operation to death or last contact. Group comparisons in survival were made using log-rank tests and Z-tests. The Cox proportional-hazards model was used to investigate various covariates, including age (< 50 vs ≥ 50 years), KPS score (< 90 vs ≥ 90), RC volume (≤ 15 vs > 15 cm 3 ), location, and side, separately for WHO Grade III and IV tumors. Statistical analysis was performed with SAS version 9.2 (SAS Institute Inc.).
To allow comparison with "historical" data, 8, 17 patients were classified using the Radiation Therapy Oncology Group recursive partitioning analysis (RTOG-RPA) Classes I−V based on age, KPS score, neurological condition, and mental status. 8, 17 results patient characteristics and survival Forty patients in the study had a WHO Grade IV tumor, and 15 patients had a Grade III tumor. One glioblastoma multiforme (GBM) patient with a Grade IV oligo- dendroglioma and 1 patient with Grade III oligoastrocytoma were also included (Table 1) . Patients with Grade III tumors were younger, more frequently female, and had a higher KPS score than patients with Grade IV tumors.
Two patients, both with Grade III tumors, refused standard radiotherapy. Four patients had recurrent tumors: 2 of them initially had a Grade II astrocytoma that later progressed to Grade III, and 2 patients initially had a The demographic characteristics of patients with Grade IV tumors in the 3 therapy Groups A, B, and C are listed in Table 1 . Group C patients tended to be older than Group A or B patients. The cumulative dose of the applied radioactivity was comparable between Groups B and C (Table  2) . Survival analysis revealed a strong tendency toward increased median OS and 12-and 24-month survival rates for Group B and particularly Group C, as compared with Group A (Fig. 2) . If Groups B and C (treated with the When all 40 GBM patients were stratified into RPA Classes III, IV, and V ( Fig. 3) , they showed median survival times of 31.6 (95% CI 15.8-59.4), 18.9 (95% CI 11.7-27.8), and 14.5 months (95% CI 11.0-16.7), respectively (log-rank test, p = 0.004; Table 3 ). These values were associated with 24-month survival rates of 70.6% (95% CI 48.9-92.2), 35.3% (95% CI 12.6-58.0), and 0%, and thus were higher than expected.
Cox proportional-hazard analysis was performed with all 40 GBM patients; variables were included only if they were significant on univariate analysis (Table 4) . Sex, age, histology, therapy groups, and RTOG-RPA class were significantly prognostic for survival on univariate analysis, whereas KPS score, volume of RC, and MGMT methylation status were not. However, the computed coefficients of these factors clearly indicated an impact on prognosis.
Despite the small number of cases, the multivariate Cox model confirmed the role of RPA class (including age) and treatment in predicting survival. In the adjusted model, patients in RPA Class IV have a 2.8-fold increased risk of dying as compared with patients in RPA Class III, and the risk was more than 6-fold higher in RPA Class V patients. The hazard ratio (HR) for the therapy Groups B+C was 0.384 (95% CI 0.180-0.822, p = 0.014) as compared with Group A, which corresponds to a 61.6% reduction in the probability of death. Fluid samples, taken from the RC in some patients, showed a stable radioimmunoconjugate for at least 5 days. In therapy Groups A and B, 5 RIT cycles were planned; in therapy Group C, only 3 cycles were planned. The percentage of patients who actually received each of the RIT cycles is presented in Fig. 1 and Table 1 . In most cases, the reason for applying less than the planned number of cycles was local recurrence together with deterioration of the patient, occlusion of the catheter, or shrinking of the RC.
additional therapies
Twenty percent of patients with Grade III tumors and 25% of those with Grade IV tumors received 1 or more cycles of chemotherapy (nitrosourea-based or temozolomide) before the first cycle of RIT. If tumor progression occurred, systemic chemotherapy was administered following RIT; this applied to 60% of patients with Grade III tumors and 56.4% of those with Grade IV tumors (procarbazine, lomustine, vincristine [PCV], n = 17; temozolomide, n = 14). Thirty-three percent of AA patients and 33% of GBM patients had a local recurrence removed during or after RIT; 4 patients had a stereotactic 125 I seed implantation. Although there were small differences in the frequency of reinterventions and chemotherapies between the 3 therapy groups, they were not significant. A univariate Cox model in the GBM subgroup excluded any significant influence of repeat surgery and chemotherapy on observed median OS. The biopsies obtained during the surgical reinterventions in 15 patients were examined histologically, and the results were divided into 3 categories: tumor, radionecrosis, and mixed tumor and radionecrosis. 27 Four of the 15 patients predominantly revealed tumor, 5 patients showed different degrees of radionecrosis, and 6 patients displayed mixed tumor and radionecrosis.
adverse events and/or toxicity
During RIT and follow-up, no Grade 3 or 4 hematological, nephrologic, or hepatic toxic effects were observed with the administration of 90 Y-mAB or 131 I-mAB. Sixteen patients developed mild and 4 patients developed moderate (Grade 1 or 2) leukopenia, thrombocytopenia, and/or erythropenia, and these resolved without further treatment (Table 5) . A mild (n = 8) or moderate (n = 2) increase in creatinine, uric acid, and/or urea; and a mild (n = 18) or moderate (n = 7) change in prothrombin time, aspartate aminotransferase, total bilirubin, gamma-glutamyl transpeptidase, alkaline phosphatase, lactate dehydrogenase, and/or creatine kinase were observed; none needed further treatment. Since some patients received chemotherapy, the precise etiology of such changes was difficult to distinguish. Additional significant adverse events included thrombosis (n = 1), pneumonia (n = 1), and skin necrosis over the subgaleal reservoir (n = 4), with 2 of the 4 instances requiring plastic surgery. In 5 cases the reservoir with the catheter had to be removed because of a seroma (n = 1), an abscess in the tumor cavity (n = 2), and/or skin necrosis (n = 3). An exchange of the reservoir was necessary in 1 case. During RIT, 9 patients developed seizures rated as Grade 2 on the CTC scale (all self-limited); 2 developed dysphasias (Grade 2); 2 developed aphasias with hemiparesis (Grade 3); 1 developed severe hemiparesis (Grade 3); and 1 developed hydrocephalus (Grade 3). Headache was reported by some patients immediately following injection of the radioactive complex into the RC. Except for the hydrocephalus, these events resolved either spontaneously or with corticosteroids; in patients with seizures, antiseizure medication was administered. (13) 11 (20) 2 (15) 2 (12) 1 (9) 3 1 (7) 4 (10) 5 (9) 1 (8) 2 (12) In the course of treatment, MRI studies were suspicious for radionecrosis in 6 patients (10.9%); 2 of these patients were treated with 90 Y-mAB and 4 patients with 131 I-mAB. These findings were supported by either FDG-or FET-PET and were confirmed by the later course. Time from the first RIT cycle to radiological signs of radionecrosis (positive MRI enhancement and negative FET-PET) ranged between 3.6 and 31 months with a median of 10.8 months. Median OS of these patients was 135.8 months.
No radionecrosis was observed below a cumulative dose of 82 mCi/3000 MBq in 33 patients. However, radionecrosis was observed in 4 (27%) of 15 patients at a cumulative dose between 82 and 135 mCi/3000-5000 MBq and in 2 (28%) of 7 patients at doses between 135 and 240 mCi/5000-9000 MBq. All patients with radiological signs of radionecrosis responded well to steroids, and no one required reoperation. All other neurological events were attributable to tumor progression.
MGMT promoter methylation and IDH1 mutation status, analyzed retrospectively in a subset of patients, showed promoter methylation in 30% of Grade III tumors and in 52% of Grade IV tumors (Table 1) . No significant difference existed in the frequency of methylation status between the 3 therapy groups. In the Cox regression model, methylation status had a coefficient of -0.708 and a HR of 0.493 but did not reach significance, most likely due to the small numbers. IDH1 mutations were found in 54% of Grade III tumors and in 22% of Grade IV tumors. The latter figure is higher than expected, probably since 1 GBM had an oligodendroglioma component and 2 others were initially designated Grade III. There was no significant difference in the mutation rate between the 3 therapy groups. All mutations were found in the group with an age < 50 years (Fisher's exact test, p = 0.001).
discussion
Intracavitary radioimmunotherapy depends on sufficient exposure of infiltrating tumor cells to the therapeutic agent. Thus, for an optimal effect the antibody conjugate should be able to reach infiltrating cells, located some distance from the resection margin. Migration of the antibody into the adjacent parenchyma occurs predominantly by diffusion, and its velocity is dependent on the diffusion gradient, the diffusion coefficient, and the width and tortuosity of the extracellular space. 1, 28 Diffusion may account for a migration of 0.15-0.6 mm/hour of linear distance in edematous tissue. 1, 11, 15, 21, 28 If the values are extrapolated, the transition time through a 20-mm tissue depth is theoretically between 40 and 160 hours.
Our study investigates the effects of repeated intracavitary radioimmunotherapy and demonstrates this concept to be feasible and efficacious. Fractionated treatment with radiolabeled anti-tenascin mAB markedly prolongs median OS in patients with GBM or AA, but particularly those with AA. Median OS in the small group with AA was 77.2 months, and 5 (33%) of the 15 patients survived 11 years and longer. All 5 of the surviving patients at the last MRI follow-up were without recurrence and able to work. To overcome heterogeneities in known prognostic factors, we restratified patient data according to the prognostic classes constructed by Curran et al. 8 These prognostic classes have been used to provide reliable "historical" controls, to which results of nonrandomized studies can be compared. 8, 18 Survival in our cohort of AA patients was markedly longer than what would be expected from appropriate RTOG-RPA Classes I-III, 8, 18 and the high percentage of long-term survivors (33%) with a KPS between 90 and 100 is particularly impressive.
Median OS in all 40 patients with GBM was 18.9 months, and it was 25.3 months in those treated with the 131 I-mAB. The corresponding 2-year survival rates were 42.5% and 52%, respectively, and 3 (7.5%) of the 40 patients are currently alive with observation times of 112, 156, and 193 months. Median OS in the RPA Classes III-V, even when analyzed conservatively with all 40 GMB patients, was markedly higher than expected given historical controls. The greatest treatment effect for GBM was seen in RPA Class III and IV with a gain in survival of 13 and 7.5 months, respectively, as compared with the RTOG data. Even in RPA Class V, the worst prognostic category, there was a survival gain of about 7 months. The survival gain and the 2-year survival probability were also superior to results obtained in the complete resection arm of the ALA trial as well as those obtained in the RT and temozolomide arm of the Stupp study. 19, 22 These positive effects become even more pronounced when only patients treated with I, are generally lower to avoid radiation-induced toxicity. Given a previous dose-escalation study in which the maximum tolerated dose to the brain was 25 mCi (925 MBq), 30 we applied an average dose of 18 mCi (666 MBq) per cycle in Group A in the present study. Although prognostic factors and the number of applied cycles were similar in Groups A and B (Table 1) , survival parameters in Group A were less favorable than in Group B and particularly Group C. In Group A there were fewer hematological adverse events, no radiological signs of radionecrosis, but nearly the same rate of neurological adverse events. Median survival was more favorable for Group B (5 cycles of 30 mCi each) and most favorable for Group C (3 cycles of 50, 40, and 30 mCi). This observation is important, since in this rapidly progressing disease 3 cycles are easier to administer than a higher number of cycles. Based on our experience, the third and/or succeeding cycles were often not feasible, and an interval shorter than 6 weeks between the cycles seems appropriate. It also appeared that the higher initial dose of radiation given in Group C had the greatest benefit for survival, but the optimal combination of the initial and subsequent doses has yet to be determined.
The Cox proportional-hazards multivariate analysis of all 40 GBM patients showed RPA status (including age) to be the strongest significant prognostic factor for patient survival. The adjusted model accounts for a survival benefit for therapy Groups B and C compared with Group A with a HR of 0.384, corresponding to a 61.6% reduction in the probability of death. Importantly IDH1, MGMT methylation status, and frequency of additional therapies were balanced between GBM therapy groups and did not skew results. No significant influence was found in the univariate Cox model for both additional therapies-repeat surgery or chemotherapy-after radiological progression. I-labeled murine 81C6 mABs in primary AA (n = 6) and GBM (n = 27). 25, 27 In a recent pilot study in which the single dose of 131 I-mAB was adapted to the volume of the RC to achieve a 44-Gy boost to the RC margin, the median OS in GBM patients was 22.6 months. 26 A study using 3 intravenous injections of 125 I-labeled antiepidermal growth factor receptor antibody reported a median OS of 14.5 months in patients with RIT alone and 20.4 months in patients treated with RIT and temozolamide. 17 
adverse events and toxicity
There appears to be an association between cumulative administered radioactivity and hematological and neurological adverse events. No Grade 3 or 4 hematological or neurological toxicity was observed with a single or repeated intracavitary dose at or below 80 mCi/2960 MBq using 131 I-conjugated antibodies. 4, 25, 29, 31 However, with a higher single dose of 100 mCi/3700 MBq into the RC, reversible hematological Grade 3 or 4 toxicity was reported in 23% of patients, and Grade 3 neurotoxicity occurred in 12% of patients, all of whom were responsive to steroids and none of whom required reoperation for radionecrosis. 3, 27 In 2 previous studies using a still higher single dose of 120 mCi (4400 MBq), 27% and 39% of the patients, respectively, had Grade 4 reversible hematological toxicities, and 15% and 39% of the patients, respectively, experienced treatment-related Grade 3 and 4 neurological toxicity, including radionecrosis requiring reoperation. 3, 25 Conversely, with fractionated application and 6-week intervals between cycles, we observed no Grade 3 or 4 hematological, nephrologic, or hepatic toxicity; a low percentage of patients experiencing Grade 3 neurological toxicity (9%); no Grade 4 neurological toxicity; and radiological signs of radionecrosis in 10.9% patients, who responded well to steroids. It must be noted, however, that many of the patients in the cited studies simultaneously received adjuvant chemotherapy, which itself has some type of Grade 3 and 4 hematological toxic effects. 34 In all cases with Grade 3 neurological deficits (hemiparesis, aphasia), the RC was in immediate proximity to the motor or language cortex, suggesting that the local radiation dose was adversely affecting adjacent tissue. This finding is in line with observations made by Akabani et al. 3 Since patients received external beam radiation therapy at 60 Gy prior to RIT, the total cumulative dose has to be considered. Akabani et al., after a single injection of 120 mCi 131 I-mAB into the RC, estimated the average absorbed doses to regions of interest 1 and 2 cm from the margins of the cavity interface to be 71 (range 26-136 Gy) and 40 Gy (range 16-68 Gy) and approximately 8 Gy for normal brain tissue. 3, 4 The wide range of the absorbed doses may be explained by the varying size of the RC volume. If the estimated doses are added to the absorbed dose from external fractionated radiotherapy, this may exceed the dose tolerance of brain tissue in some patients. In a recent survey on re-irradiation of recurrent glioma, radiation-induced necrosis occurred with conventional fractionation beyond a cumulative EQD2 of around 100 Gy (EQD2 = equivalent total dose when applied in 2-Gy fractions, estimated using the linear quadratic model). 32 The radiation dose that can be tolerated increases with higher conformality (fractionated stereotactic radiotherapy) and smaller treatment volumes (linear accelerator [LINAC]-based stereotactic radiosurgery). 6, 32 In summary, repeated injections at similar or even higher cumulative doses appear to be associated with less hematological and neurological adverse events than a single high-dose application. This underlines the importance of biological repair mechanisms of brain tissue between the cycles. Unfortunately, data are lacking for the repair half-time of brain tissue radiation damage. 32 
study limitations
This study is limited by several factors. It is a single-institution nonrandomized trial with a small sample size and most likely contains imbalances and bias. There is also a certain selection effect, as only patients with small residual tumor volumes were eligible for study inclusion. We made our best attempt to carefully analyze all differences and took statistical measures to adjust for such bias. We must emphasize that despite the small number of cases, the multivariate Cox model clearly confirmed the role of RPA class (including age) and treatment in predicting survival. In particular, restratification of the data according to RTOG-RPA Classes I-V, as part of the initial study design, showed a promising survival benefit compared with historical controls. Since retrospective analysis of MGMT and IDH1 was not possible in all tumors, these incomplete data are used mainly to exclude major differences among the subgroups.
conclusions
In this study with a limited case number and selected patient group, the median survival of AA and GBM patients treated with intracavitary fractionated applications of radiolabeled anti-tenascin mABs favorably exceeds that of historical controls (RTOG-RPA) 8, 18 treated with conventional radiotherapy and chemotherapy, as well as other recently published approaches, [33] [34] [35] even after adjusting for established prognostic parameters. The results need to be validated by a larger or randomized trial. With the doses used in our study, adverse events remained well controlled. Several factors can be further optimized: adjusting the activity of the labeled mAB to the cavity volume, reducing the time between cycles, using a higher initial dose of radiation, and adding the administration of temozolomide. Currently, a randomized trial is in preparation to further assess this promising approach.
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